JUN 75716 | CAS#184475-71-6

MedKoo Cat#: 555326 | Name: JUN 75716

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

JUN 75716, also known as O-Desmorpholinopropyl Gefitinib is a metabolite of gefitinib, which is an EGFR inhibitor. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

JUN 75716

CAS#184475-71-6

Theoretical Analysis

MedKoo Cat#: 555326

Name: JUN 75716

CAS#: 184475-71-6

Chemical Formula: C15H11ClFN3O2

Exact Mass: 319.0524

Molecular Weight: 319.72

Elemental Analysis: C, 56.35; H, 3.47; Cl, 11.09; F, 5.94; N, 13.14; O, 10.01

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
5g	USD 550.00	2 Weeks
10g	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

O-Desmorpholinopropyl Gefitinib; JUN 75716; JUN-75716; JUN75716; M295820; M-295820; M 295820;

IUPAC/Chemical Name

4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinol

InChi Key

JLVTVCRXFMLUIF-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H11ClFN3O2/c1-22-14-6-12-9(5-13(14)21)15(19-7-18-12)20-8-2-3-11(17)10(16)4-8/h2-7,21H,1H3,(H,18,19,20)

SMILES Code

OC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC

Appearance

Beige to Light Brown Solid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 319.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hiraide M, Minowa Y, Nakano Y, Suzuki K, Shiga T, Nishio M, Miyoshi J, Takahashi H, Hama T. Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity. J Oncol Pharm Pract. 2018 Sep 26:1078155218801061. doi: 10.1177/1078155218801061. [Epub ahead of print] PubMed PMID: 30253730. 2: Chu X, Li Y, Zhu Z. A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib. J Thorac Oncol. 2018 Oct;13(10):e211-e214. doi: 10.1016/j.jtho.2018.05.022. PubMed PMID: 30244858. 3: Omori S, Oyakawa T, Naito T, Takahashi T. Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC. J Thorac Oncol. 2018 Oct;13(10):e207-e208. doi: 10.1016/j.jtho.2018.05.020. PubMed PMID: 30244856. 4: Mao J, Ma L, Shen Y, Zhu K, Zhang R, Xi W, Ruan Z, Luo C, Chen Z, Xi X, Chen S. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. Cell Death Dis. 2018 Sep 20;9(10):963. doi: 10.1038/s41419-018-0998-7. PubMed PMID: 30237564; PubMed Central PMCID: PMC6147786. 5: Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C. Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells. Oncotarget. 2018 Aug 24;9(66):32667-32679. doi: 10.18632/oncotarget.25994. eCollection 2018 Aug 24. PubMed PMID: 30220973; PubMed Central PMCID: PMC6135698. 6: Ohbayashi N, Murayama K, Kato-Murayama M, Kukimoto-Niino M, Uejima T, Matsuda T, Ohsawa N, Yokoyoma S, Nojima H, Shirouzu M. Structural Basis for the Inhibition of Cyclin G-Associated Kinase by Gefitinib. ChemistryOpen. 2018 Sep 10;7(9):721-727. doi: 10.1002/open.201800177. eCollection 2018 Sep. PubMed PMID: 30214852; PubMed Central PMCID: PMC6129943. 7: Yi H, Li S, Li H, Wang P, Zheng H, Cheng X. Gefitinib induces non-small cell lung cancer H1650 cell apoptosis through downregulating tumor necrosis factor-related apoptosis-inducing ligand expression levels. Oncol Lett. 2018 Oct;16(4):4768-4772. doi: 10.3892/ol.2018.9162. Epub 2018 Jul 17. PubMed PMID: 30214609; PubMed Central PMCID: PMC6126167. 8: Burki TK. Preliminary activity of capmatinib with gefitinib in NSCLC. Lancet Oncol. 2018 Sep 6. pii: S1470-2045(18)30678-8. doi: 10.1016/S1470-2045(18)30678-8. [Epub ahead of print] PubMed PMID: 30197173. 9: Tang X, Jiang J, Zhu J, He N, Tan J. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer. Mol Genet Genomics. 2018 Sep 8. doi: 10.1007/s00438-018-1489-3. [Epub ahead of print] PubMed PMID: 30196354. 10: Huang YP, Jiang YW, Chen HY, Hsiao YT, Peng SF, Chou YC, Yang JL, Hsia TC, Chung JG. Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro. Anticancer Res. 2018 Sep;38(9):5165-5176. doi: 10.21873/anticanres.12839. PubMed PMID: 30194164. 11: Capmatinib plus Gefitinib Is Active in EGFR-Mutant MET-Amplified Tumors. Cancer Discov. 2018 Sep 7. doi: 10.1158/2159-8290.CD-RW2018-152. [Epub ahead of print] PubMed PMID: 30194064. 12: Chang TC, Chin YT, Nana AW, Wang SH, Liao YM, Chen YR, Shih YJ, Changou CA, Yang YS, Wang K, Whang-Peng J, Wang LS, Stain SC, Shih A, Lin HY, Wu CH, Davis PJ. Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation. Horm Cancer. 2018 Sep 5. doi: 10.1007/s12672-018-0341-x. [Epub ahead of print] PubMed PMID: 30187356. 13: Xu YJ, Shi ZL, Wang Z, Du L, Cheng SZ, Zhang X. Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. J Thorac Oncol. 2018 Sep;13(9):e165-e168. doi: 10.1016/j.jtho.2018.01.015. PubMed PMID: 30166013. 14: Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JMW, Robertson JF, Ellis IO, Nicholson RI. Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2018 Aug 30;20(1):98. doi: 10.1186/s13058-018-0999-6. PubMed PMID: 30165904; PubMed Central PMCID: PMC6117898. 15: Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Aug 29:JCO2018777326. doi: 10.1200/JCO.2018.77.7326. [Epub ahead of print] PubMed PMID: 30156984. 16: Pan YH, Jiao L, Lin CY, Lu CH, Li L, Chen HY, Wang YB, He Y. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Biologics. 2018 Aug 20;12:75-86. doi: 10.2147/BTT.S166867. eCollection 2018. PubMed PMID: 30154647; PubMed Central PMCID: PMC6108345. 17: Zhang H, Li Q, Zhu X, Wu M, Li C, Li X, Liu C, Shen Z, Ding Y, Hua S. Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. Front Pharmacol. 2018 Aug 7;9:849. doi: 10.3389/fphar.2018.00849. eCollection 2018. PubMed PMID: 30131694; PubMed Central PMCID: PMC6090208. 18: Jin S, He J, Li J, Guo R, Shu Y, Liu P. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1. Thorac Cancer. 2018 Aug 20. doi: 10.1111/1759-7714.12830. [Epub ahead of print] PubMed PMID: 30126075. 19: Uruga H, Moriguchi S, Takahashi Y, Ogawa K, Murase K, Mochizuki S, Hanada S, Takaya H, Miyamoto A, Morokawa N, Kishi K. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis. BMC Cancer. 2018 Aug 16;18(1):825. doi: 10.1186/s12885-018-4743-5. PubMed PMID: 30115025; PubMed Central PMCID: PMC6097412. 20: Li J, Liu X, Yuan C. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report. Mol Clin Oncol. 2018 Sep;9(3):321-324. doi: 10.3892/mco.2018.1666. Epub 2018 Jul 5. PubMed PMID: 30112177; PubMed Central PMCID: PMC6090575.